An interventional study of Combination group and Standard group in Cardiac Arrest, Out-Of-Hospital Cardiac Arrest and Emergency Medical Services, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital — 6 open to participants now, 7 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · National Taiwan University Hospital.
Among the 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital, this one is one of 2 that started in 2024, is one of 8 with no phase, and was the 11th registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →6 of the 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18–60
National Taiwan University Hospital · Sites in Taiwan
Ages 18–99 · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18–99
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 1,344 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 311 across the 8 interventional studies, 350 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
1 of the studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856018National Taiwan University HospitalArtificial Intelligence Cerebral Gray-white Matter Ratio Module Usage in Hsinchu District Hsinchu District Using an Artificial Intelligence Cerebral Gray-white Matter Ratio Module | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is a randomized controlled clinical research design, The hypothesis P-I-C-O of the study is: For adult patients in the Taipei City and New Taipei City communities who have suffered sudden non-traumatic death and have been resuscitated by advanced paramedics, the intervention group that receives combined drug treatment (epinephrine, vasopressin, methylprednisolone) has a better rate of sustained recovery of spontaneous circulation (ROSC) (primary outcome) and long-term survival status (secondary outcomes) compared to the control group that receives single drug treatment (epinephrine).
The global and Taiwanese survival rates for patients following an out-of-hospital cardiac arrest (OHCA) are less than 10%. The emergency medical system (EMS) plays a crucial role in patient outcomes after OHCA, providing prehospital cardiopulmonary resuscitation, defibrillation, and medication. Among these medications, the combination of epinephrine, vasopressin, and methylprednisolone holds the most potential to improve patient survival rates following OHCA.
This study aims to compare the effect of standard epinephrine therapy with a combination of epinephrine, vasopressin, and methylprednisolone administered to OHCA patients. This comparison will be made through a randomized clinical trial (RCT) within the EMS of Taipei City and New Taipei City.
Throughout the research plan, we will conduct a prehospital RCT to answer the following question (in P-I-C-O format): Will adult non-traumatic OHCA patients resuscitated by paramedics in a prehospital setting have a better chance of sustained recovery of spontaneous circulation (primary outcome), and improved survival status (secondary outcomes), if they receive combination therapy (i.e., standard doses of epinephrine, 20U of vasopressin after each dose of epinephrine up to a maximum of 80U, and one dose of 40mg methylprednisolone after the first dose of epinephrine) compared to those who receive standard doses of epinephrine? We estimate a sample size of 1,344 OHCA patients to detect a difference in the primary outcome. Based on the background data from the EMS regions under study, we expect the enrollment to take approximately 30 months to complete.
This study is referred to as the "OHCA-REVIVES" trial, which stands for A randomized clinical trial of patient outcomes following Out-of-Hospital Cardiac Arrest Receiving Epinephrine Versus In-together Vasopressin, Epinephrine, and Steroid. The anticipated results from the "OHCA-REVIVES trial" will help determine the optimal strategy for prehospital medication, and will undoubtedly have a significant impact on resuscitation science. Through these efforts, we aim to improve the outcomes of OHCA patients.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
This study's planned enrollment of 1,344 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Browse Out-of-Hospital Cardiac Arrest studies →National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Compared within Out-of-Hospital Cardiac Arrest, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Arrest. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Combined drug treatment: includes epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes, vasopressin (Pitressin® 20Unints/vial) every 3-5 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial). The method of administration is as follows: after the first administration of epinephrine (Adrenaline® 1mg/vial) to patients with cardiac arrest before hospital arrival, vasopressin (Pitressin® 20Unints/vial) and methylprednisolone (Solu-Medrol® 40mg/vial) are given simultaneously; thereafter, every 3-5 minutes, 1 mg (1 dose) of (Adrenaline® 1mg/vial) is given, along with 20 Units (1 dose) of vasopressin (Pitressin® 20Unints/vial) up to a maximum of 4 doses (a total of 80 Units) of vasopressin can be given before hospital arrival.
Drug: Combination group
Standard drug treatment: epinephrine (Adrenaline® 1mg/vial). According to international resuscitation guidelines ( Advanced Cardiac Life Support, ACLS), patients with cardiac arrest before hospital arrival are given 1 mg (1 dose) of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes.
Drug: Standard group
Combination of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes, vasopressin (Pitressin® 20Unints/vial) every 3-5 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
standard doses of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes
Rate of sustained return of spontaneous circulation (ROSC)
Return of spontaneous circulation (ROSC) is the restart of a sustained heart rhythm measured by pulsation and vital signs that permeate the body after a cardiac arrest. Sustained ROSC ≥ 2 hours has been used as an surrogate to survival to hospital admission in many overcrowded emergency departments (ED).
Time frame: estimated 2 hours
Rate of prehospital return of spontaneous circulation (ROSC)
presence of ROSC prior to arrival at emergency department (ED)
Time frame: estimated 1 hour
Rate of survival to hospital discharge
survival to hospital admission, and without in-hospital death
Time frame: estimated 30 days
Rate of survival with favorable neurologic status
Good neurologic status (defined as Cerebral-Performance Category (CPC) score 1 and 2) at hospital discharge
Time frame: estimated 30 days
Plan to share: Yes — Upon completion of the study, the sharing of Individual Participant Data (IPD) will be made available in accordance with local privacy protection laws.
Supporting information: Study protocol
Time frame: Upon completion of the study, estimated at the end of 2026, the sharing of Individual Participant Data (IPD) will be made available following local privacy protection laws.
Access criteria: reasonable request to the corresponding authors.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.
Of 93 non-industry interventional studies with no phase under Out-of-Hospital Cardiac Arrest, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 24 months is below that.
Counting every sponsor, half of 95 studies reached it within 34 months; a quarter within 19 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Out-of-Hospital Cardiac Arrest →
National Taiwan University Hospital →